Exposure to two or more adverse childhood experiences roughly doubles odds of firearm ownership in adulthood
TUESDAY, Aug. 20, 2024 (HealthDay News) — Cumulative adverse childhood experience (ACE) exposure is associated with higher odds of household firearm ownership in adulthood, according to a study published online Aug. 15 in JAMA Network Open.
Alexander Testa, Ph.D., from the University of Texas Health Science Center at Houston, and colleagues used survey data from 1,709 adults from the 2022 Nevada Behavioral Risk Factor Surveillance System to examine the association between ACEs and household firearm ownership among U.S. adults.
The researchers found that household firearm ownership was lowest among respondents with no ACEs (30.8 percent) and highest among those with four or more ACEs (49.8 percent). There was a significant association between having multiple ACEs and household firearm ownership compared with no ACEs. For specific ACE items, household illegal drug use (adjusted odds ratio, 1.57) and verbal abuse (adjusted odds ratio, 1.54) were associated with household firearm ownership. The association of four or more ACEs and household firearm ownership was significantly similar among females and males.
“The relationship may be due to a heightened sense of vulnerability to physical violence and greater perceived threats to personal safety associated with a traumatic childhood, which lead individuals to seek self-protection,” the authors write.
Updated Guideline Developed for Diagnosis, Management of Childhood Nocturnal Enuresis
Nearly 2 in 3 Poison Exposures in Young Children May Not Need the ED
Longer Reproductive Lifespan Tied to Lower Bronchiectasis Risk in Postmenopausal Women
Workplace Psychological Stress Linked to Erectile Function in Young Men
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer
Body Fat Percentage May Be Better Indicator of Men"s Reproductive Health Than BMI
Early BPH Outcomes Comparable for p-ThuLEP and Open Prostatectomy
Aglatimagene Besadenovec + Valacyclovir Ups DFS in Localized Prostate Cancer